The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10851359 B1

PDF
Full Text
Expired
Date of Patent:
Dec. 01, 2020

Filed:

Mar. 24, 2016
Applicant:

Medizinische Hochschule Hannover, Hannover, DE;

Inventors:

Rita Gerardy-Schahn, Hiddenhausen, DE;

Florian Kuehnel, Hannover, DE;

Nikolas Martin, Springe, DE;

David Schwarzer, Hannover, DE;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/24 (2006.01); C07K 14/005 (2006.01); A61K 35/761 (2015.01); A61K 38/16 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 9/2402 (2013.01); A61K 35/761 (2013.01); A61K 38/162 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C12N 15/86 (2013.01); C12Y 302/01129 (2013.01); C07K 2319/00 (2013.01); C07K 2319/035 (2013.01); C07K 2319/33 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10071 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10332 (2013.01); C12N 2795/00022 (2013.01); C12N 2795/00043 (2013.01); C12N 2795/00071 (2013.01);
Abstract

The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.


Find Patent Forward Citations

Loading…